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bstract
The adverse effects of radiation therapy, often integrated with chemotherapy and/or targeted therapies, on the skin include severe acute and
hronic dermatitis associated with pain, discomfort, itching, and burning, and may heavily affect patients’ quality of life. The management of
hese skin adverse effects in head and neck cancer patients (HNCPs) are very heterogeneous due to the lack of shared rigorous classification
ystems and evidence based treatments.
A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition
nd management of dermatitis in HNCPs treated with radiotherapy with or without systemic therapies in order to improve skin toxicity
anagement. The Delphi Appropriateness Method was used. External expert reviewers then evaluated the conclusions carefully according to
heir area of expertise.
This paper offers contains seven clusters of statements about the management of dermatitis in HNCPs and a review of recent literature on
hese topics.
 2015 Elsevier Ireland Ltd. All rights reserved.
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.  Introduction
The improvements in head and neck cancer (HNC) treat-
ent have led to an increase in the overall response rate
ORR), progression-free survival (PFS), and overall survival
OS) [1].
Unfortunately, the use of radiation therapy, often inte-
rated with chemotherapy and/or targeted therapies, must
eal with severe acute and chronic skin toxicity often asso-
iated with pain, discomfort, itching, and burning, heavily
ffecting patients’ quality of life [2–4].
Significant acute skin toxicity may affect up to 95% of
hese patients, which sometimes impacts negatively on the
roper adherence to the treatment protocol [5].
Contemporary radiation technologies allow the skin to
eceive only a fraction of the total dose that is delivered to
he target, but in the case of HNC the skin is so near target
olumes that radio-dermatitis cannot be avoided.
Furthermore, the association of radio-sensitizing sys-
emic therapies (e.g. 5-fluorouracil, Cetuximab, etc.)
t
ck cancer; Biodermatitis; EGFRi
ncreases this toxicity [3,6–8] and may modify the tim-
ng and clinical aspects of radio-dermatitis effects. For
nstance, radio-induced dry desquamation may be aggra-
ated and its timing shortened by the Cetuximab-induced
erosis [9]. Similarly, radio-induced moist desquama-
ion may be complicated by chemotherapy or epidermal
rowth factor receptor inhibitors that predispose HNCPs
o systemic inflammation response [10] and to infection
11].
The management of these skin adverse effects in HNCPs
s very heterogeneous because of the lack of shared rigor-
us classification systems and evidence based treatments. A
ecent study from Belgium [12] showed that the disclosure
nd implementation of a skin protocol enhanced standard-
zation in Flanders improved adhesion to evidence-based
uidelines and led to the disappearance of out-dated ritualistic
ractices.For all these reasons Italian medical oncologists, radia-
ion oncologists and nurses met with the aim of reaching a
onsensus on a clinical definition and management of acute
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adiation dermatitis in HNCPs, particularly in regard to those
tatements with limited evidence.
The results of the literature review and the statements
hat obtained a consensus are reported and discussed in this
aper.
.  Materials  and  methods
The Delphi Appropriateness method was used for this
onsensus [13].
The panel, a group of 32 multidisciplinary experts
medical oncologists, radiation oncologists, dermatologists,
utritionists, and nurses), met in Milan on February
7th–18th, 2013 and appointed a facilitator board of six
xpert members, from different clinical settings (three radi-
tion oncologists, 1 medical oncologist, and two nurses).
he facilitator board performed a systematic review of the
iterature on skin toxicity.
The MEDLINE database was searched for studies pub-
ished from 1990 to March 2013 containing the terms skin
oxicity, skin reaction, actinic dermatitis, head and neck can-
er, chemotherapy, Cetuximab and radiotherapy (RT). The
iterature search was limited to articles in Italian, English
nd French about human cancers treated with RT.
Potentially relevant abstracts presented at annual meet-
ngs of the American Society of Clinical Oncology (ASCO),
merican Society for Radiation Oncology (ASTRO) and the
uropean Society of Medical Oncology (ESMO) were also
xamined.
The study selection included the following:
(a) Observational and prospective studies about assess-
ent and treatment; (b) randomized, double-blind, placebo-
ontrolled, or uncontrolled studies; (c) retrospective and
ncontrolled studies; (d) systematic reviews and meta-
nalyses; and (e) consensus guidelines. Furthermore, the
lectronic search results were supplemented by manual
xamination of reference lists from selected articles.
On the basis of this literature review, the facilitators iden-
ified a number of key statements.
All the experts rated these statements through a two-round
rocess. A scale of four steps was used, where 1 was defined
s “high consensus”, two was defined as “low consensus”,
hree was defined as “no consensus”, and four was chosen by
anellists when they felt unable to express an opinion.
A web meeting was held before the second rating, where
tatements were discussed. The statements that received a
eak or no approval (less than 75% of votes) were redefined
ccording to the observations of panellists. The second rat-
ngs were analyzed to identify the statements that reached a
onsensus.
Each expert (including facilitators) was equally weighted
n scoring the statements.
Then, external radiation oncologists (JAL, R-JB), a med-
cal oncologist (CP), and a dermatologist (GG) reviewed the
tatements.
t
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The panellists had a second meeting in Milan on 5 May
014 in order to approve the final version of the statements.
. Results
Consensus-reached statements are listed in Table 1
. Comments
.1.  General  statements
. The most commonly-used RTOG/EORTC and CTCAE
v.3-4.3 grading systems do not capture the symptoms or
impact due to RT-associated systemic therapies on radia-
tion dermatitis.
. When it is necessary to capture symptoms, other scales,
such as RISRAS or Skindex-16, could be used addition-
ally [2,4,14–16].
The use of a common, sensitive, specific, and easy tool
is fundamental for the classification and the management
of all possible skin toxicities.
Some commonly used grading tools for the assess-
ment and documentation of radio-dermatitis include the
Radiation Therapy Oncology Group (RTOG)/European
Organization for Research and Treatment of Cancer
(EORTC) toxicity criteria [17], the Common Terminol-
ogy Criteria for Adverse Events, version 3 and 4.03
(CTCAE) [18,19], the Skin Toxicity Assessment Tool
[20], the Radiation-Induced Skin Reaction Assessment
Scale [2,15], and the Skindex-16 scale [16].
Most of the tools are observer assessments that do
not capture the symptoms or the skin-reaction impacts
on Activities of Daily Living (ADL) or on the clinical
management. On the contrary, the recent classification of
CTCAE v. 4 published in May 2009 evaluates the impact
of the Adverse Events on the patient’s ADL and on the
clinical management [21] (see Table 2).
. When it is necessary to capture the impact of systemic
biological therapy on radiation dermatitis, it is advisable to
use the in-field bio-radiation skin-toxicity grading score.
Radiation dermatitis developing in patients receiving
etuximab concomitantly with RT for locally advanced
quamous cell HNC is now recognized as having different
athophysiological and clinical characteristics with respect
o the radiation dermatitis due to RT alone [22,23].
While version 4 of the NCI “Cancer Therapy Evaluation
rogram” (CTCAE v.4) graded new systemic dermatological
oxicities (e.g. “Rash acneiform” hierarchically grouped into
he “Skin and subcutaneous tissue disorders” (System Organ
lass), which are more appropriate for grading systemic
GFR-inhibitor (EGFRi) toxicities than previous versions
24,25], there has not yet been any grading system which
170 E.G. Russi et al. / Critical Reviews in Oncology/Hematology 96 (2015) 167–182
Table 1
Consensus-reached statements.
Cluster
Phase
Description Whom is it in charge of?
1 Before CRT 1. General statements
1. The most commonly-used RTOG/EORTC and CTCAE v.3-4.3 grading
systems do not capture the symptoms or impact due to RT-associated
systemic therapies on radiation dermatitis.
2. When it is necessary to capture symptoms, other scales, such as RISRAS
or Skindex-16, could be used additionally.
3. When it is necessary to capture the impact of systemic biological therapy
on radiation dermatitis, it is advisable to use the in-field bio-radiation
skin-toxicity grading score
Oncology Physician–Nurse
2 Before CRT 1. Risk factors (factors that place patients at increased risk of severe skin
toxicity, and that should be considered at the baseline skin assessment)
1.1. Host factors:
1. Personal factors such as skin friction, nutritional status, age, race and
ethnicity, sun exposure, smoking and pre-existing skin disease (such as
atopic eczema or psoriasis, or autoimmune bullous diseases).
2. Co-morbidities (such as rheumatoid arthritis, lupus erythematosis, or
scleroderma, etc.)
3. Diagnosis of gene repair disorders (for example Xeroderma pigmentosum,
ataxia-telangiectasia, Fanconi anaemia, Nijmegen syndrome, etc.)
1.2. Treatment-related factors:
1. Skin total dose, Fraction size, type and energy of radiation and the use of
bolus.
2. Chemotherapy or other medical photosensitizing concomitant therapies
Oncology Physician–Nurse–Patient
3 Baseline evaluation 2. Baseline assessment (successively, during CRT, at least weekly) and
preventive recommendations
2.1. General recommendations:
1. A detailed medical history relating to personal and family risk factors
should be carefully collected.
2. It is important to establish a proper technique to minimize the dose
delivered to the skin.
3. Avoid radio-sensitizing drugs during radiation treatment, if clinically
indicated: when chemotherapy is not concurrent (paclitaxel, docetaxel), a
period of almost seven days has to be respected (see point 2b2).
4. Caution must be used with non-necessary common photosensitizing
drugs and sun exposure during chemo-radiation (see point 2b2).
5. Patients must avoid smoking.
2.2. Preventive hygiene recommendations:
1. Washing with lukewarm water and a mild soap (pH-neutral or
non-alkaline soap) can be used as routine care for all patients receiving
radiation therapy.
2. Shaving with a sharp, disposable multi-blade wet razor or with a
non-traumatizing electric razor.
3. Avoid micro-traumas in irradiated area or tapes and adhesives.
4. Preventive non-steroidal treatments: A moisturizing cream based on urea
or anionic polar phospholipid is advised. Trolamine and Aloe Vera are not
recommended.
5. It is not advisable to use cream or other skin products from 1 to 4 h before
treatment so as to avoid “build-up” effects.
2.3. Recommendations if risk factors are present.
1. Maintain an optimal control of co-morbidities as diabetes and nutritional
status; a close collaboration with the diabetologist and the dietician is
needed.
2. If active signs/symptoms of rheumatoid arthritis, systemic lupus
erythematosis, psoriatic arthritis, or scleroderma are diagnosed, consider
using conventional fractionation, reducing total dose where possible,
keeping treatment volumes as small as possible and keeping a high level of
caution with multimodality treatments, especially when RT is associated to
concurrent chemotherapy or biological anticancer treatments. A close
liaison with the rheumatologist and dermatologist is needed.
3. If gene repair disorders are diagnosed (for example Xeroderma
pigmentosum, ataxia-telangiectasia, Fanconi anaemia, Nijmegen syndrome,
etc.) consider avoiding RT.
Oncology Physician–Nurse–Patient
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Table 1 (Continued )
Cluster
Phase
Description Whom is it in charge of?
4 During CRT 3. Topical steroidal agents Oncology Physician–Nurse
1. The use of corticosteroid creams for treating itching or irritation should
be limited over time as they can cause thinning of the skin and bacterial
infections.
2. The use of corticosteroid creams in the prevention of skin reactions is
not advisable as they can cause thinning of the skin and bacterial infections
5 During CRT 4. Dressing and advanced medications Oncology Physician–Nurse
1. Even though there is insufficient evidence to support a recommendation
for using dressings or advanced medications, these can be used to protect
irradiated skin from trauma or, in the case of wet desquamation, in order to
control pain, bleeding, and exudates.
2. Protection of ulcerated parts can be provided with hydrocolloid films
after having cleaned the skin. The ultrathin films can be maintained during
radiation. This dressing should be removed when it is saturated with
exudate.
3. Hydrofibers, calcium alginate dressings, and polyurethane or silicone
foams could be used when the exudate is very abundant. No evidence
exists to support one product over another.
4. When crusts or crustose exudations are present, the debridement of
crusts may help to reduce the risk of super-infection and bleeding and may
help with pain management.
6 During CRT 5. Infection management Oncology Physician–Nurse
1. Consider topical or systemic antimicrobials if positive cultures or
documented infections are present.
2. An empirical systemic antibiotic therapy must be used as soon as
possible when two altered parameters of Systemic Inflammatory Response
Syndrome (SIRS) and/or other signs of systemic inflammatory response to
infection (such as inflammatory, haemodynamic, organ dysfunction and
tissue perfusion parameters) coexist with a suspected infection
7 During CRT 6. Serious toxicity and treatment interruption. Oncology Physician–Nurse
6.1. Grade III toxicity
© In the case of toxicity of grade 3 or less every effort should be made to
not stop the radiation treatment.
6.2. Grade IV toxicity
1. Consider interrupting both systemic and radiation treatments. If the
patient has been treated with Cetuximab and RT, Cetuximab should be
interrupted until the skin reaction has resolved to at least grade II
ecialist
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42. Refer patient for wound care or wound sp
ssesses the severity of Adverse Events (AEs) due to the
ssociation of bio-therapies with RT.
In 2011, Bernier et al. proposed a new classification [26]
hat considers the adverse effects of both radio-dermatitis and
etuximab on “in-field” skin. The limits of this classification
re the fact that it does not take into account the impact of the
Es on the patient’s activities of daily living (ADL) and their
mpacts on the clinical management as required by CTCAE
.4. Furthermore, it considers only the effects of Cetuximab
ithout considering the possibility that new biological anti-
ancer therapies – with different AEs – might be used in the
ear future.
For this reason, a group of US and European experts
27] proposed a new classification that considers the
TCAE recommendations regarding ADL and that does
ot limit the grades exclusively to Cetuximab but extend
hem to the possible effects of new future biothera-
ies (at the moment non predictable) on the irradiated
kin.
1 management.
Even though the latter scale has not yet been validated
28], the panellists suggested adopting it, in the absence of a
ore appropriate one.
.2.  Risk  factors
The factors that may influence the response of the patient’s
kin to RT have been grouped into two categories: host fac-
ors depending on the patient’s biological characteristics and
reatment-related factors. These factors may place the patient
t increased risk of dermatitis and should be considered at the
aseline skin assessment.
.2.1.  Host  factors. Personal factors such as skin friction, nutritional status,
age, race and ethnicity, sun exposure, smoking and pre-
existing skin disease (such as atopic eczema or psoriasis,
or autoimmune bullous diseases).
172 E.G. Russi et al. / Critical Reviews in Oncology/Hematology 96 (2015) 167–182
Table 2
In-field adverse events due to radiation therapy with or without biological therapies.
Grade 1 Grade 2 Grade 3 Grade 4
NCI–CTCAE, v4.03
general criteria
Mild; asymptomatic or
mild symptoms;
Clinical or diagnostic
observations only;
intervention not
indicated.
Moderate;
Minimal, local or
non-invasive
intervention indicated;
Limiting
age-appropriate
instrumental ADL (refer
to preparing meals,
shopping for groceries
or clothes, using the
telephone, managing
money, etc.
Severe or medically
significant but not
immediately life-threatening;
Hospitalization or
prolongation of
hospitalization indicated;
disabling;
Limiting self care AD (refer
to bathing, dressing and
undressing, feeding self,
using the toilet, taking
medications, and not
bedridden
Life-threatening
consequences;
Urgent intervention indicated
Radiation dermatitis Faint erythema or dry
desquamation.
Moderate to brisk
erythema; patchy moist
desquamation, mostly
confined to skin folds
and creases; moderate
oedema
Moist desquamation in areas
other than skin folds and
creases; bleeding induced by
minor trauma or abrasion
Life-threatening
consequences; skin necrosis
or ulceration of full-thickness
dermis;
Spontaneous bleeding from
involved site; skin graft
indicated
Bio-radiation
dermatitis [27]
Faint erythema or dry
desquamation; and
lesions due to
bio-treatment (e.g.
xerosis, papules,
pustules, and other
clinical signs), which
may or may not be
associated with
symptoms of pruritus or
tenderness.
No limiting
age-appropriate ADL.
Moderate to brisk
erythema; patchy moist
desquamation in folds
and creases; lesions due
to bio-treatment (e.g.
crusts, papules,
pustules, and other
clinical signs) mostly
confined to less than
50% of radiated area;
bleeding lesions with
friction or trauma.
Limiting
.
Moist desquamation in areas
other than skin folds and
creases; extensive (>50% of
involved field) confluent
lesions due to bio-treatment
(e.g. crusts, papules, pustules,
and other clinical signs)
associated to bleeding by
minor trauma or abrasion.
Limiting selfcare.
Life-threatening
consequences: skin necrosis
or ulceration of full thickness
dermis;
Extensive (>50% of involved
field) confluent lesions due to
bio-treatment (e.g. crusts,
papules, pustules, and other
clinical signs) associated to
signs of spontaneous
bleeding.
Systemic inflammation
response syndrome (SIRS)
2
3age-appropriate
instrumental ADL
The skin integrity (including the presence of skin atro-
phy), body site (such as the neck skin where the epidermis
is thin and subjected to friction from overlapping skin
folds [23]), obesity [29], nutritional status, age, sun expo-
sure, exposure to extreme temperatures, and smoking, are
all factors that increase the risk of radiation-induced tox-
icity [30]. Race and ethnicity are also considered factors
that may affect the skin response to RT [31,32].
Pre-existing inflammatory skin disease may favour the
development of severe radiation dermatitis, although no
formal studies have confirmed this hypothesis. In particu-
lar, atopic eczema, which very frequently affects the head
and neck area, is associated with skin that is very sensi-
tive to a variety of environmental factors including heat,
solar radiation, detergents, and water. In addition, ioniz-
ing radiation may elicit or exacerbate autoimmune bullous
disease such as pemphigus [33–35].
. Co-morbidities (such as rheumatoid arthritis, lupus ery-
thematosis, or scleroderma, etc.)Pre-existing connective tissue or autoimmune diseases,
including scleroderma, lupus erythematosis, and per-
haps rheumatoid arthritis (RA), unpredictably predispose
w
i
a
bpatients to the development of severe radiation dermatitis
[36–39]. At any rate, the studies that support this state-
ment are retrospective with small numbers of patients
and use different scoring scales for complications. As a
consequence, these factors may contribute to an overes-
timation of true radiation-induced morbidity, but the fact
that peripheral lymphocytes from patients with lupus ery-
thematosis, RA and systemic sclerosis have significantly
greater DNA damage after irradiation than do those from
control subjects [40,41]. It is in any case advisable to be
prudent in particular when the connective tissue disease is
active or associated to an uncontrolled hypertension and
type I diabetes [42].
. Diagnosis of gene repair disorders (for example
Xeroderma pigmentosum, ataxia-telangiectasia, Fanconi
anaemia, Nijmegen syndrome, etc.)
As ionizing radiation produces DNA damage, patients
ith impaired cellular DNA repair capabilities are at
ncreased risk. Patients with ataxia-telangiectasia, a rare
utosomal-recessive disorder resulting from mutations in
oth copies of the ATM gene, are predisposed to develop
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evere complications after RT. It is hypothesized that some
atients who develop serious, unanticipated radiation der-
atitis may be heterozygous for this mutated ATM gene
approximately 1% of the general population) [43,44].
Other rare diseases with reduced cellular DNA repair
apability, such as hereditary nevoid basal cell carcinoma
yndrome (Gorlin syndrome), Fanconi’s anaemia, Bloom
yndrome, Xeroderma pigmentosum, Nijmegen breakage
yndrome [45], familial polyposis, Gardner’s syndrome,
ereditary malignant melanoma, dysplastic nevus syndrome,
nd DNA ligase IV deficiency [45–56], may expose patients
o severe risks and either RT should be avoided altogether or
he skin-doses should be selected with great care.
.2.2. Treatment-related  factors
. Skin total dose, Fraction size, type and energy of radiation
and the use of bolus
Treatment-related factors such as skin total dose, frac-
tion size, type and energy of radiation can impact skin
reactions: larger treatment volume, larger total dose of
radiation, larger fraction size (>2 Gy per fraction), and
higher surface dose (bolused or low energy beams) can
increase skin toxicity [5,57–60].
. Chemotherapy or other medical photosensitizing con-
comitant therapies
Also chemotherapy or other medical radio-sensitizing or
hotosensitizing concomitant therapies may also increase
cute toxicity to the skin [3,7,61–65].
Radio-sensitizers are drugs that given either immediately
efore/during, or less than 7 days after radiation, cause
ncreased cellular damage and impaired repair [62]. Pacli-
axel or docetaxel when used in conjunction with RT produce
ynergistic cutaneous toxicity that is both schedule- and dose-
ependent [61].
Photosensitizers are drugs that are activated by UVA,
VB, and visible range beams and their photo-activated com-
ounds damage the surrounding cutaneous tissue [65].
.3.  Baseline  assessment  (successively,  during  CRT,  at
east weekly)  and  preventive  recommendations
.3.1.  General  recommendations
. A detailed medical history relating to personal and family
risk factors should be carefully collected.
. It is important to establish a proper technique to minimize
the dose delivered to the skin [57,66–68].
In head and neck IMRT plans, high skin dose [67] is
consequent to multiple tangential-to-skin beams and to
the bolus effect of immobilization devices. Some Authors
suggest excluding the skin over uninvolved neck nodes
from target volumes in order to reduce the dose to the
skin by 6–7% [57,69].At any rate, every effort must be taken to avoid high
doses to the skin. The use of advanced technologies for
evaluating the skin dose might be considered [70,71].ogy/Hematology 96 (2015) 167–182 173
. Avoid radio-sensitizing drugs during radiation treatment,
if clinically indicated: when chemotherapy is not concur-
rent (paclitaxel, docetaxel), a period of almost seven days
has to be respected (see point 2b2).
. Caution must be used with non-necessary common
photosensitizing drugs and sun exposure during chemo-
radiation (see point 2b2).
. Patients must avoid smoking [72].
The dangerous effects of tobacco on irradiated skin [72],
mmune response [73], and repairing capacity of the tissue
74] are well known.
.3.2.  Preventive  hygienic  recommendations
. Washing with lukewarm water and a mild soap (pH-
neutral or non-alkaline soap) can be used as routine care
for all patients receiving radiation therapy.
Washing with lukewarm water and a mild pH-neutral
or non-alkaline soap should not be restricted as routine
care for patients receiving radiation therapy [75–78].
. Shaving with a sharp, disposable multi-blade wet razor or
with a non-traumatizing electric razor.
It is advisable to shave with a sharp, disinfected wet
razor or with a non-traumatizing electric razor [26].
. Avoid micro-traumas in irradiated area or tapes and adhe-
sives.
Physical traumas, for example due to clothes, expo-
sure to direct sunlight or exposure to extreme temperatures
and the use of skin irritants such as alcohol-based lotions
and perfumes should be avoided. This recommendation is
particularly important if epidermal growth-factor receptor
inhibitors are used [26].
. Preventive non-steroidal treatments: A moisturizing
cream based on urea or anionic polar phospholipid is
advised. Trolamine and Aloe Vera are not recommended.
Many non-steroidal topical treatments or oral systemic
therapies have been used in radio-dermatitis prevention.
They have been used especially on breast skin, but it is
generally believed that these results can be reported also
for head-and-neck skin.
Oral  preventive  treatment
Oral  systemic therapies such as zinc supplements
[79], pentoxifylline [80], and Wobe-Mugos E (i.e.
proteolytic enzymes containing 100 mg papain, 40 mg
trypsin, and 40 mg chymotrypsin that should provide
anti-inflammatory and analgesic effects) [81–83] are not
sufficiently supported by the literature results in radio-
dermatitis prophylaxis [84].
Non-steroidal  preventive  topical  treatments
Lipiderm  [85], vitamin C solution [86], chamomile
cream [87], almond ointment [87], petroleum based
ointment (Aquaphor) [88–90], hyaluronic acid [90–95],
sucralfate and its derivatives [93,96–98], glutathione and
anthocyanin (Raygel) [99], LED (light-emitting diode
lasers) [100], Theta cream [101], and Dexpanthenol (a
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provitamin of B5) [91,101,102] did not demonstrate a
sufficient benefit in terms of dermatitis prevention.
On the contrary, aloe vera [103–106] and trolamine
[85,88–90,107,108] are not recommended [84]. In par-
ticular aloe vera is not a moisturizer [109], thus it may be
contraindicated in the case of xerosis.
Calendula is likely to be effective [107,110] but it is
difficult to apply [107] [84].
An anti-inflammatory drug from Chinese medicine
(Lian Bai liquid) in a non-blinded trial of 126 participants
[111] reported the effectiveness in preventing and treating
radio-induced dermatitis. This drug needs confirming in
further multicentre trials.
Silver sulfadiazine cream was shown to be active in
preventing radio-dermatitis [112,113], but its use as pro-
phylactic management is not recommended because of
concerns about sensitivity or resistance with overuse
[109,114].
Finally, urea lotion [115,116], and anionic
phospholipid-based cream [117] were shown to be
more effective than the control arms that used conven-
tional dry skin care and aloe vera gel respectively. Urea
cream should be used only with a urea concentration of
5–10%.
Preventive dressing:  barrier  films
Barrier films have been used in order to reduce trauma
and retain moisture in the maintenance of intact skin dur-
ing RT.
In a breast cancer study by Graham et al. [118], a
spray-on no-sting barrier was evaluated as a prophylac-
tic treatment in the prevention of moist desquamation (vs.
glycerine cream) and it was associated with a lower total
skin toxicity score (p  = 0.005) and a lower prevalence of
pruritus (p  = 0.01). Successively, the same Authors, test-
ing a moisturizing alcohol-free barrier film (MDBC), did
not find any advantages vs. glycerine cream [119]. Der-
mofilm (a micro-thin emollient skin protector, containing
hydrophilic and lipophilic agents) also was used and,
although a symptomatic improvement occurred, a larger
trial was advocated but never performed [120].
Safetac-based silicon dressings (Mepilex-Lite® dress-
ings) provide mechanical protection from trauma,
similarly to no-sting barriers, and showed a significant
30–40% decrease in skin reaction severity in breast cancer
patients [121–123]. However, Mepilex-Lite dressings did
not affect moist desquamation rates when used to manage
existing skin reactions [123]. This failure was attributed
by the Authors to the necessity to remove Mepilex-Lite
dressings during radiation delivery because of their thick-
ness and their bolus effect [122]. Thus, the same Authors
used Mepitel Film (a thinner Safetac-based dressing) with
a clinically insignificant bolus effect of 0.12 mm [124].
This film could be safely left on during radiation deliv-
ery and it was shown that it prevented the occurrence of
radiation-induced moist desquamation and decreased the
extent of skin reaction severity by 92%. These dressings
o
r
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have never been used as a preventive tool in HNCPs where
the irregularity of skin surface makes these devices diffi-
cult to be left in site (in the personal experience of one of
the authors: R.E.).
Silver dressing (a non-adherent rayon and polyester
material coated with nano-crystalline silver) does not
seem to be useful as a preventive treatment [125].
. It is not advisable to use cream or other skin products from
1 to 4 h before treatment so as to avoid “build-up” effects.
While the practice of avoiding the use of products on the
kin from 1 to 4 h before treatment may have a theoretical
oundation in order to avoid the so called “build-up” effect,
o evidence exists to support this practice [126].
Topical Vitamin K1 in prophylactic or reactive treatment
ay reduce the incidence of grade-3 toxicity and improve
etuximab compliance. Indeed, Vitamin K activates EGFR
ignalling. Preclinical studies have shown that vitamin K3
ompletely abrogated EGFR inhibition in vitro and was asso-
iated with up-regulation of phosphorylated EGFRs in the
kin when used in topically-applied cream [127,128]. Some
linical evidence has been presented on the beneficial effect
f vitamin K1 cream on patients experiencing a severe anti-
GFR-induced acne-like rash [129–132]. Yet, the panellists
etain there is not sufficient evidence to recommend it in
NCPs and future prospective multicentre randomized trials
re needed.
.3.3.  Recommendations  if  risk  factors  are  present.
. Maintain an optimal control of co-morbidities as diabetes
and nutritional status; a close collaboration with the dia-
betologist and the dietician is needed.
. If active signs/symptoms of rheumatoid arthritis, systemic
lupus erythematosis, psoriatic arthritis, or scleroderma
are diagnosed, consider using conventional fractionation,
reducing total dose where possible, keeping treatment vol-
umes as small as possible and keeping a high level of
caution with multimodality treatments, especially when
RT is associated to concurrent chemotherapy or biological
anticancer treatments. A close liaison with the rheumatol-
ogist and dermatologist is needed.
. If gene repair disorders are diagnosed (for example
Xeroderma pigmentosum, ataxia-telangiectasia, Fanconi
anaemia, Nijmegen syndrome, etc.) consider avoiding RT.
Particular attention is needed for those patients with active
onnective tissue disease and/or a combination of uncon-
rolled hypertension with type I diabetes [42].
Apparently healthy HNCPs, carrying heterozygote dis-
ases with a reduced DNA-repairing capability in their family
istory, should be treated with prudently selected doses or,
hen possible, with a non-radiation oncological approach.
RT must be avoided in patients with Ataxia-telangiectasiar suffering from those diseases with a reduced cellular DNA
epair capability (see point 2a3).
It is essential to evaluate the HNCP’s skin prior to any
reatment, especially those areas that will be irradiated.
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very pre-existing skin disease, such as atopic eczema, acne,
osacea, ichthyosis, and psoriasis, must be documented, espe-
ially if using EGFRis [22].
.4.  Topical  steroidal  agents
. 4.4a. The use of corticosteroid creams for treating itching
or irritation should be limited over time as they can cause
thinning of the skin and bacterial infections.
. 4.4b. The use of corticosteroid creams in the prevention of
skin reactions is not advisable as they can cause thinning
of the skin and bacterial infections.
Corticosteroids have potent anti-inflammatory effects
such as vasoconstriction, reduced capillary permeability, and
nhibition of leucocyte migration [133,134]) in many derma-
ological conditions, thus they have often been prescribed
n both the prevention and management of radiation skin
eactions.
The use of corticosteroid creams in the management or
revention of skin reactions has provided contrasting results
102,135–140]. However, this use must be limited over time
ecause it can cause thinning of the skin and favour bacterial
nfections [77,78,141,142]. Current evidence is insufficient
o support or refute this practice.
While topical glucocorticosteroid can help in the treat-
ent of xerosis and reduce water loss from the skin in
atients receiving panitumumab [143], there is no consen-
us regarding the efficacy of these agents on irradiated
kin [102,139]. Moreover, some authors suggest that topi-
al glucocorticoids may increase the cutaneous toxicity of
GFRis [127]. In any case, it is prudently advisable to
imit the use of glucocorticosteroids to short periods of time
1–2 weeks) [22,26].
.5.  Dressings  and  advanced  medications
. Even though there is insufficient evidence to support a
recommendation for using dressings or advanced medi-
cations, these can be used to protect irradiated skin from
trauma or, in the case of wet desquamation, in order to
control pain, bleeding, and exudates.
. Protection of ulcerated parts can be provided with hydro-
colloid films after having cleaned the skin. The ultrathin
films can be maintained during radiation. This dressing
should be removed when it is saturated with exudate.
. Hydrofibers, calcium alginate dressings, and polyurethane
or silicone foams could be used when the exudate is very
abundant. No evidence exists to support one product over
another.
. When crusts or crustose exudations are present, the
debridement of crusts may help to reduce the risk of
super-infection and bleeding and may help with pain man-
agement
The use of hydrogel and hydrocolloid dressings has
een reported in the case of moist desquamation. Hydrogel
2ogy/Hematology 96 (2015) 167–182 175
acks supporting evidence of superior efficacy when tested
gainst either gentian violet [144] or drying dressings [145].
lthough hydrocolloid dressings do not seem to be advanta-
eous in terms of healing time, they appear to be useful in
erms of pain control in severe Cetuximab/RT dermal toxicity
4,9].
Finally, in a small study, a silver-leaf dressing (effective for
he prevention of radio-dermatitis in anal or gynaecological
ancer patients [146]) was used on HNCP skin: no differences
etween the dressing and silver sulfadiazine cream in terms
f severity of skin toxicity or healing was obtained, but pain
ontrol was improved using silver-leaf dressing [112].
.6.  Infection  management
. 4.6a. Consider topical or systemic antimicrobials if posi-
tive cultures or documented infections are present.
. 4.6b. An empirical systemic antibiotic therapy must be
used as soon as possible when two altered parameters
of Systemic Inflammatory Response Syndrome (SIRS)
and/or other signs of systemic inflammatory response to
infection (such as inflammatory, haemodynamic, organ
dysfunction and tissue perfusion parameters [147,148])
coexist with a suspected infection.
SIRS parameters need monitoring. Indeed, even if two
ositive SIRS parameters are not specific of sepsis [148–150],
hey may help physicians to graduate the urgency of interven-
ion, to promptly activate the search for infection and for other
igns of systemic inflammatory response to infection (such as
nflammatory, haemodynamic, organ dysfunction and tissue
erfusion parameters [147,148]), in order to shorten the time
o start antibiotic administration [151].
In cases of dermatitis of grade 2/3, when a super-
nfection is suspected without systemic-inflammatory-
esponse involvement, antiseptics and/or topical antibiotics
such as clindamycin and erythromycin) may be helpful, but it
ight be useful to obtain an antibiogram of exudative lesions.
If serious toxicity is associated to a systemic inflammatory
esponse, culture data should be obtained before starting any
mpirical antibiotic treatment [151].
.7.  Serious  toxicity  and  treatment  interruption
.7.1.  Grade  III  toxicity
 In the case of toxicity of grade III or less, every effort
should be made in order not to avoid interrupting the radi-
ation treatment.
.7.2. Grade  IV  toxicity
. Consider interrupting both systemic and radiation treat-
ments. If the patient has been treated with Cetuximab
and RT, Cetuximab should be interrupted until the skin
reaction has resolved to at least grade II.
. Refer patient for wound care or wound specialist
management.
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Any interruption of radiation therapy may result in a
ecreased risk of local oncological control. Thus, in the pres-
nce of grade three toxicity the panel suggests continuing RT
ecause the advantages consequent to local-toxicity recov-
ring might be annulled by the negative effects of tumour
e-growth [152,153]. Of course, the symptoms of local tox-
city must be monitored/controlled and the panel suggests
hat HNCPs might be hospitalized in order that the spe-
ific antineoplastic treatments can continue safely by limiting
nterruption as much as possible.
In the case of Grade IV toxicity, the main cause of life-
hreatening consequences is due to the systemic inflammation
esponse to infection. Thus, the presence of grade IV and/or
epsis should induce the interruption of all systemic (CT or
GFRi) and local (RT) antineoplastic treatments.
.  Considerations  for  the  future
Some novelties are coming out from the genetic and epi-
enetic research area. Patient populations having a genetic
redisposition to radiation dermatitis could be identified
154,155]. Indeed, the object of on-going researches is
ome gene-clusters, not associated with other genetic dis-
ases/abnormalities [156–158]. These gene-clusters may be
resent in “healthy” patients (meaning patients who are oth-
rwise healthy beyond having a malignancy) and they might
redict sensitivity to radiation. This area should deserve more
ttention because this strategy might have a big impact in
he next future such as in other radiation toxicities (e.g. oral
ucositis [159], skin toxicity [154,157]).
Furthermore, the “in-field” toxicity assessment tools need
o be refined (CTCAE v 4.0 and bioradiation dermatitis) in
ight of the next imminent version of CTCAE.
On this purpose, the scientific community should wonder
bout the concern that the incorporation of ADL components
n the scoring scales might result in more of a subjective
ssessment. This fact might result in a significant drift from
he previous scoring scales that were based more on physi-
al appearances of skin lesions. Indeed, the ADL components
ight further complicate the process of establishing effective
reatments for dermatitis. In fact, the addition of the ADL may
lso be incorporating symptoms arising from more than one
adiation toxicity. For example, when a patient is unable to
et dressed it might be in consequence of the fact that either
e could be physically limited in range of motion or it may be
ue to pain or to fatigue or to other standalone toxicities. All of
hese causes might be separate from the effects of dermatitis.
hese confounding problems could make it difficult to assess
reatments for the dermatitis toxicity, specifically. Further-
ore, pre-clinical research models, used to screen potential
ompounds, are designed to mirror clinical scoring scales.
onsequently, ADL components could be beyond the phys-
cal appearances of dermatitis and this fact could make it
ore difficult to determine an efficacy signal for providing
he appropriate treatment.
F
dogy/Hematology 96 (2015) 167–182
Finally, the biodermatitis scale, proposed by European
xperts and suggested in this consensus, needs validating
n a clinical trial. The on-going Gortec 2014-02 trial (Per-
onal communication) is a multinational project that has
een prospectively evaluating the rate of severe dermatitis in
atients receiving radiation plus Cetuximab for unresectable
ead and neck cancer. This prospective trial has also the aim
o validate the bio-radiation dermatitis scale by comparing it
o the assessment scale of NCI-CTC v 4.3.
.  Conclusions
Skin toxicity is a very common occurrence in inte-
rated treatments for HNCPs, and it may result in pain,
iscomfort, irritation, itching and finally delays or interrup-
ions of antineoplastic treatments, influencing the prognosis
f potentially curable tumours. Many studies have been
onducted, but there are many uncertainties. As a con-
equence, clinical management varies from centre to
entre.
Our review aimed to obtain some indications for the
anagement of skin toxicity in those situations where
vidence is poor and it further tried to draw up recommenda-
ions/suggestions for HNCPs based on the consensus among
ultidisciplinary health professionals. The adopted Delphi
trategy provides a highly structured and transparent process
o obtain anonymous feedback. The authors believe that this
pproach, with the support of external experts in this field,
llowed participants to give recommendations more safely in
hose situation where it is necessary to act without the support
f strong evidence.
The main aim is to standardize diagnostic and treatment
ehaviour among centres participating in multicentre trials.
Clearly, the main limit of this study is the fact that part
f the evidence is obtained from non-HNCP literature, and
any studies are small and/or retrospective.
In the future, an increased understanding of the mecha-
isms of cellular damage may lead to a better prevention of
his toxicity.
Acute in-field skin toxicity management in head and neck
ancer patients treated with radiotherapy and chemotherapy
r EGFR inhibitors: literature review and consensus
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